Recent health news highlights include a CDC team assessing bird flu in Washington state farm workers, CVS's leadership change ...

Novavax (NVAX) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.

However, Novavax's shares recently dropped by about 20% in one day after it announced a clinical setback. The biotech's stock ...

An analysis by Li Tao, MD, MS, PhD, director of real-world evidence at Gilead Sciences, and colleagues looked at statistical ...

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Novavax, Inc. (“Novavax” or ...

Sep. 25, 2024 — Almost everyone knows about HIV. Fewer people know about its relative, HTLV-1. However, HTLV-1 can cause serious illnesses, including cancer. To develop ways to combat this virus ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Novavax announced Wednesday that the Food and Drug Administration (FDA) has placed a clinical hold on its application for a ...

Analyst Eric Joseph of J.P. Morgan maintained a Sell rating on Novavax (NVAX – Research Report), retaining the price target of $9.00.

The FDA approved the company's COVID vaccine in October 2023. The stock has gained 111% in the year to date, while the S&P 500 SPX has gained 22%. This content was created by MarketWatch, which is ...

WASHINGTON - The US Food and Drug Administration on Aug 30 granted emergency use authorisation for an updated version of Novavax's Covid-19 shot. The updated vaccine is authorised for use in ...